股东们批准了Coeptis治疗公司分裂为一家技术基础设施公司和一家生物技术分流公司,后者被安排在没有IPO的情况下在NASDAQ上公布。 Shareholders approved Coeptis Therapeutics' split into a tech infrastructure firm and a biotech spin-out, with the latter set to list on NASDAQ without an IPO.

科普蒂斯治疗公司 (NASDAQ:COEP) 的股东批准了一项重大重组,将公司分为两个实体:一项价值6.6亿美元的技术基础设施业务,现在以COEP标签作为Z-Squared Inc.运营,以及一项价值7500万美元的生物技术分拆,专注于包括DVX201和SNAP-CAR平台在内的细胞疗法. Shareholders of Coeptis Therapeutics (NASDAQ: COEP) have approved a major restructuring that splits the company into two entities: a $660 million technology infrastructure business, now operating as Z-Squared Inc. under the COEP ticker, and a $75 million biotech spin-out focused on cell therapies including DVX201 and the SNAP-CAR platform. 幸存公司保留21%的所有权,Z-Squared股东持有79%的所有权。 The surviving company retains 21% ownership, with Z-Squared shareholders holding 79%. 这笔交易保留了1亿美元的税收损失转折,使投资者能够接触到稳定的基础设施收入和高增长的生物技术开发,生物技术实体被安排在没有传统IPO的情况下列入NASDAQ。 The deal preserves $100 million in tax-loss carryforwards and allows investors exposure to both stable infrastructure revenue and high-growth biotech development, with the biotech entity set to list on NASDAQ without a traditional IPO. 该交易最初在2025年证交会申报中披露,正在接近结账。 The transaction, first disclosed in 2025 SEC filings, is moving toward closing.